Pharmacological treatment of acquired QT prolongation and torsades de pointes.
Thomas SH, Behr ER.
Br J Clin Pharmacol. 2016 Mar;81(3):420-7. doi: 10.1111/bcp.12726. Epub 2015 Oct 26.
Torsades de Pointes in Patients with Polymyalgia Rheumatica.
Lazzerini PE, Bertolozzi I, Acampa M, Fulceri R, Laghi-Pasini F, Capecchi PL.
Curr Pharm Des. 2018;24(3):323-340. doi: 10.2174/1381612824666180111111124.
[Torsades de pointes].
Guize L, Iliou MC, Bayet G, Lavergne T, Le Heuzey JY.
Arch Mal Coeur Vaiss. 1993 May;86(5 Suppl):769-76.
Torsades de Pointes.
Bishop D.
Confed Aust Crit Care Nurses J. 1990 Dec;3(4):32-5. doi: 10.1016/s1033-3355(11)80053-6.
Torsades de pointes: arrhythmia, syndrome, or chimera? A perspective in the light of the Lambeth Conventions.
Curtis MJ.
Cardiovasc Drugs Ther. 1991 Feb;5(1):191-200. doi: 10.1007/BF03029820.
In brief: PPIs and Torsades de Pointes.
[No authors listed]
Med Lett Drugs Ther. 2016 Dec 5;58(1509):153.
Propoxyphene-induced torsades de pointes.
Adler A, Viskin S, Bhuiyan ZA, Eisenberg E, Rosso R.
Heart Rhythm. 2011 Dec;8(12):1952-4. doi: 10.1016/j.hrthm.2011.07.015. Epub 2011 Jul 18.
Torsades de pointes.
Solomons HD.
Cardiovasc J Afr. 2011 Jul-Aug;22(4):217.
Torsades de pointes in a woman presenting with syncope.
Wong SW, Ng S, Tan JH.
Ann Acad Med Singap. 2022 Jan;51(1):64-66. doi: 10.47102/annals-acadmedsg.2021393.
Torsades de pointes: prevention and therapy.
Keren A, Tzivoni D.
Cardiovasc Drugs Ther. 1991 Apr;5(2):509-13. doi: 10.1007/BF03029778.
